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Objectives: Sleep apnea is associated with hyperuricemia owing to hypoxia-induced nucleotide turnover.  We assessed the relation of incident sleep apnea to the risk of incident gout.  
Methods: Using data from The Health Improvement Network in the United Kingdom we identified individuals with a first-ever physician diagnosis of sleep apnea.  For each sleep apnea patient, up to five non-sleep apnea individuals were matched on sex, age, birth year, body mass index (+0.5 kg/m2), and year of sleep apnea diagnosis.  We estimated the incidence rates of gout and examined the relation of sleep apnea to the risk of incident gout using a Cox proportional hazards model, adjusting for potential confounders. In addition, we assessed the rate difference in gout due to sleep apnea using an additive hazard model.
Results: Among 9865 patients with newly-diagnosed sleep apnea and 43,598 comparators we identified 270 incident cases of gout over one year of follow-up, resulting in incidence rates of 8.4/1000 and 4.8/1000 person-years, respectively.  The crude and multivariate rate ratios of incident gout for sleep apnea were 1.7 (95% CI: 1.3-2.2) and 1.5 (95% CI: 1.1-2.1), respectively.  The corresponding rate differences were 3.6 (95% CI: 1.6-5.6) and 2.8 (95% CI: 0.7-4.9) per 1000 person-years. The effect of sleep apnea persisted across subgroups.      





Gout is a common inflammatory arthritis caused by hyperuricemia.  The prevalence of gout has increased over the past few decades to 3.9% in the US() and 2.5% in the UK.()  Similar trends have been found in other countries as well. ADDIN EN.CITE ()  Furthermore, gout carries a substantial comorbidity burden, particularly from cardiovascular-metabolic conditions. ADDIN EN.CITE () 

The risk of gout attacks during the night is 2.4 times higher than in the daytime.()  Among several explanations that have been put forth for this nocturnal risk, one is the potential role of sleep apnea, which is common among obese men with multiple comorbidities, a typical profile of gout patients. ADDIN EN.CITE () To date, several observational studies have reported that patients with sleep apnea have a high prevalence of hyperuricemia (up to 50%). ADDIN EN.CITE () In a cross-sectional study, Roddy et al. found that the prevalence of sleep apnea was higher among gout patients as compared with non-gout individuals.()  Despite these suggestive data, it is unknown whether sleep apnea is associated with an increased risk of incident gout and if so, what the magnitude of association is.  
 




The Health Improvement Network (THIN) is a computerized medical record database from general practices in the United Kingdom (UK).  Data on approximately 10.2 million patients from 580 general practices are systematically recorded by general practitioners (GPs) and sent anonymously to THIN.  The computerized information includes demographics, details from GP visits, diagnoses from specialist referrals and hospital admissions, results of laboratory tests, and additional systematically recorded health information including height, weight, blood pressure, smoking status, and vaccinations.  The Read classification is used to code specific diagnoses, and a drug dictionary based on data from the Multilex classification is used to code drugs.  Health information is recorded on site at each practice using a computerized system with quality control procedures to maintain high data completion rates and accuracy.  

Study Design and Cohort Assembling
We conducted a cohort study to examine the relation of incident sleep apnea to the risk of incident gout.  Eligible subjects included individuals aged between 20-89 years who had a first-ever diagnosis of sleep apnea identified by Read codes (i.e., incident sleep apnea) between January 2000 and September 30, 2013.  Study cohort members were further required to have ≥2 years of continuous enrollment with the general practice and have at least one GP visit within the 2 years prior to cohort entry.  Subjects with a history of either gout or sleep apnea before entry were ineligible.    

For each subject with incident sleep apnea (i.e., index subject), up to five individuals who had no sleep apnea (i.e., comparison cohort) at the time the index subject was diagnosed with sleep apnea (i.e., index date) were selected and matched on sex, age, and birth year.  Considering that high BMI is a strong risk factor for both sleep apnea and the development of gout, and that the distribution of BMI among patients with sleep apnea is likely to be very different from those without sleep apnea, the comparison cohort was also matched to the index subject on BMI within + 0.5kg/m2 to minimize the imbalance of BMI between the two cohorts.  Participants entered the cohort when all inclusion criteria were met or on the matched date for subjects in the comparison cohort (index dates), and were followed until subjects either developed gout, died, the follow-up reached one year, or the study period ended (i.e., December 31, 2013), whichever came first.  

Assessment of Outcome
A subject was considered to have had incident gout at the first recording by a physician after the date of entry into the study cohort.  The date of gout onset was defined as the date of the first diagnosis of gout.  To evaluate the robustness of our gout case ascertainment, we carried out a sensitivity analysis restricting people with gout to those receiving anti-gout treatment.  To this end, we used the following operational definition: identified within 90 days of a first-ever diagnosis of gout, any anti-gout treatment (allopurinol, colchicine, probenecid, febuxostat, or sulfinpyrazone), or a prescription of a non-steroidal anti-inflammatory drug on the same day of gout diagnosis.  A similar case definition of gout has been shown to have a validity of 90% in the General Practice Research Database. ADDIN EN.CITE (, )

Assessment of Covariates 
From the THIN database we obtained information on socio-demographic and anthropometric characteristics (i.e., age, sex, date of birth, and BMI) and lifestyle factors (i.e., alcohol use), comorbidities (i.e., chronic renal disease, diabetes, hypertension, ischaemic heart disease), and medication use (i.e., aspirin, diuretics, and losartan) within one year before the index date.  The presence of comorbidities was defined using Read codes for diagnoses as recorded by the GPs.  In addition, we ascertained the number of visits to a GP in the year before the index date.
Statistical Analysis
We calculated incidence rates of gout for each cohort by dividing the number of cases of incident gout by the person-years of follow-up.  We plotted Kaplan-Meier survival curves to determine the cumulative incidence rate of gout for each cohort.  Cox proportional hazard regression models were used to calculate hazard ratios after accounting for matched clusters (age, sex, entry date, and BMI).  In the multivariable model, we adjusted for all available potential confounders (i.e., alcohol consumption, comorbidities [i.e., chronic renal disease, diabetes, hypertension, and ischemic heart disease], medication use [i.e., aspirin, diuretics, and losartan], and the number of GP visits.  Further, in all multivariable models, we adjusted for BMI as a continuous variable in order to help eliminate residual confounding.  In addition, we examined the rate difference between subjects with sleep apnea and subjects in the comparison cohort using an additive hazard model.()  
We further assessed potential subgroup effects of sleep apnea according to sex, age group (> 60 years vs. > 60 years), and obesity status (BMI <30 kg/m2 vs. BMI ≥ 30 kg/m2).  We determined the statistical significance of potential subgroup effects by testing the significance of the interaction terms added to our final multivariable models.  In a sensitivity analysis, we evaluated whether the association between sleep apnea and the risk of gout varied when a more restrictive definition for the diagnosis of incident gout was applied, as described previously. ADDIN EN.CITE (, )  For all effect estimates, we calculated 95% confidence intervals (CIs).
For all analyses, missing values for covariate (i.e., alcohol use) were imputed by a sequential regression method based on a set of covariates as predictors (IVEware for SAS, version 9.2; SAS Institute, Cary, NC, USA). To minimize random error, we imputed five datasets and then combined estimates from these datasets (). 
RESULTS
	The cohort included 9865 patients with newly-diagnosed sleep apnea and 43,598 matched individuals without sleep apnea.  The mean age of the cohort was 54 years, and 72% were men.  The baseline characteristics of the two cohorts are shown in Table 1.  Sleep apnea patients tended to have more comorbidities, more use of aspirin, diuretics, and losartan, and more frequent GP visits.  

The cumulative incidence of gout is depicted in Figure 1, and the incidence rate and rate ratios and differences for incident gout according to study cohort are shown in Table 2.  During the one-year follow-up period, 270 subjects (76 among the sleep apnea cohort and 194 in the comparison cohort) developed incident gout, and the median age at the time of gout diagnosis was 60 years (range, 25 to 86).  The incidence rate of gout was 8.4 per 1000 person-years in the sleep apnea cohort and 4.8 per 1000 person-years in the comparison cohort.  Compared with those without sleep apnea, the crude rate ratio (RR) for incident gout among those with sleep apnea was 1.7 (95% confidence interval (CI): 1.3-2.2).  Adjusting for other potential confounders did not change the effect estimate materially (Table 2).  The crude rate difference of incident gout between sleep apnea patients and the comparison cohort was 3.6 (95% CI: 1.6-5.6) per 1000 person-years, and the adjusted rate difference was 2.8 (95% CI: 0.7-4.9) per 1000 person-years (Table 2).

An increased risk of incident gout from sleep apnea persisted across subgroups by sex, age, and obesity status (Table 3). The multivariable-adjusted effect estimates (either the RR or rate difference) of sleep apnea on the risk of incident gout were not modified by these risk factors (all p values for interaction > 0.05).  
In our sensitivity analysis, restricting gout cases to those receiving anti-gout treatment (n=200) showed that the effect estimate of either the RR or rate difference persisted (RR=1.4, 95% CI: 1.0-2.0; rate difference=1.5, 95% CI: 0.2-3.1 per 1000 person-years).   

DISCUSSION
In this large general practice cohort representative of the UK population, we found that the risk of gout is higher among patients with sleep apnea compared to those without the condition.  These findings were independent of BMI, lifestyle factors, and other known risk factors.  The current study provides the first general population evidence for an independent association between sleep apnea and the risk for gout and supports its potential role behind the nocturnal onset of gout flares.  Furthermore, these findings call for the investigation of the potential benefits of correcting sleep apnea-induced hypoxia on the risk of hyperuricemia and gout flares. 

The observed increased risk of gout was 60% higher among patients with sleep apnea in ratio scale, as compared with individuals who were at a very high risk of developing gout (4.8 per 1000 person-years) with a high BMI level (mean, 32.2 kg/m2), whereas the absolute difference in the incidence rate of gout was approximately 3 cases per 1000 person-years.  Such a risk is much higher than that reported in other studies, such as the Rochester Epidemiology Project (<1 per 1000 person-years)() or the Health Professionals Follow-up Study (<2 per 1000 person-years) ADDIN EN.CITE ().  

Several biological mechanisms linking sleep apnea to the risk of gout have been postulated.  Hypoxia associated with sleep apnea can enhance nucleotide turnover, thereby generating purines, which are metabolized to uric acid. ADDIN EN.CITE (, , )  As such, up to 50% of sleep apnea patients have been found to have hyperuricemia  ADDIN EN.CITE (, ) and thus, sleep apnea could predispose individuals to gout attacks, as observed in our study.  Furthermore, physiologic studies have reported that individuals with sleep-associated hypoxia showed an increased urinary uric acid excretion:creatinine (UA:Cr) ratio (an indicator for transient uric acid loading()) overnight, whereas controls with normal sleep study findings showed a decreased UA:Cr ratio overnight.()  Improvement of sleep apnea-associated hypoxia (with continuous positive airway pressure [CPAP]) was accompanied by a decrease in the overnight change in the UA:Cr ratio. ADDIN EN.CITE (, )  As our findings indicate that these physiologic impacts on uric acid levels can be translated into the risk of gout, and as sleep apnea is particularly common among those with the typical profile of gout patients, effective treatment of sleep apnea-associated hypoxia could add considerably to gout management.  To that effect, our findings call for future studies to evaluate the effect of CPAP (and other effective measures for sleep apnea) on the serum uric acid levels and the risk of gout flares among gout patients.    

Our study has several strengths and limitations.  We used data collected from a representative sample of the UK population; thus, our study findings are likely to be generalizable.  We attempted to adjust appropriately for known confounders, particularly BMI, through study design (i.e., matching) as well as by statistical modelling, to minimize non-comparability between the comparison groups.  Because the definition of gout was based on doctors’ diagnoses, a certain level of misclassification is inevitable.  However, such misclassification is likely to be non-differential and consequently dilutes the association we found.  Furthermore, when we used a physician diagnosis of gout combined with anti-gout medication use (which has previously shown a validity of 90%)  ADDIN EN.CITE (, ), our results did not change materially.  
Finally, we also used Read codes to identify patients with incident sleep apnea. In the UK, a diagnosis of sleep apnea is entered into the patient’s record after referral to a sleep clinic. ADDIN EN.CITE () Therefore, a diagnosis of sleep apnea in the THIN database is likely to be correct.  On the other hand, it is conceivable that sleep apnea may be under-diagnosed. Under such circumstances our effect estimates may have been under-estimated, because individuals in the comparison cohort (with a mean BMI of 32.2 kg/m2) may have had undiagnosed sleep apnea, thus contributing to the risk of gout.  
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Table 1. Baseline Characteristics According to Sleep Apnea Status

Baseline Characteristics	Sleep Apnea Cohort(n=9865)	Comparison Cohort(n=43,598)




BMI (kg/m2, mean + SD)	33.4+6.6	32.2+5.8
		
Alcohol consumption (%)		
   Non-drinkers	11.9	10.6
   Ex-drinkers	2.9	2.5
   Current drinkers	57.9	60.0














Ischemic heart disease (%)	11.4	8.8
		








Table 2. Association between Sleep Apnea and the Risk of Incident Gout over One Year Follow-up 







Incidence rate per 1000 person-years	8.4	4.8
		
Age-, sex-, entry time-, and BMI-matched rate ratio	1.7 (1.3-2.2)	1.0 (reference)
		
Multivariable rate ratio(95% CI)	1.5 (1.1-2.1)	1.0 (reference)
		
Age-, sex-, entry time-, and BMI-matched rate difference per 1000 person-years (95% CI)	3.6 (1.6-5.6)	0.0 (reference)
		
Multivariable rate difference* per 1000 person-years (95% CI)	2.8 (0.7-4.9)	0.0 (reference)














Table 3. Association between Sleep Apnea and the Risk of Incident Gout in Subgroups by Sex, Age, and Obesity Status 

Risk factors	Status of Sleep Apnea	No. ofSubjects	Incident Rate of Gout (1/1000 PYs)	Adjusted RR(95% CI)**	Adjusted RD*(95% CI)**
Sex					
   Men	No	31338	5.9	1.0 (referent)	0.0 (referent)
   Men	Yes	7107	9.8	1.4 (1.1-2.0)	2.8 (0.2-5.8)
					
   Women	No	12260	2.0	1.0 (referent)	0.0 (referent)
   Women	Yes	2758	4.8	2.3 (0.9-5.9)	2.3 (-0.6-5.3)
					
Age (years)					
   < 60 	No	30179	3.6	1.0 (referent)	0.0 (referent)
   < 60	Yes	6881	6.2	1.4 (0.9-2.1)	2.1 (0.0, 4.2)
					
   > 60 	No	13419	7.5	1.0 (referent)	0.0 (referent)
   > 60	Yes	2984	13.6	1.6 (1.0-2.5)	4.4 (0.0-9.1)
					
Obesity 					
   No	No	16181	3.7	1.0 (referent)	0.0 (referent)
   No	Yes	3219	6.8	1.8 (1.0-3.2)	2.6 (-0.4-5.9)
					
   Yes	No	27417	5.5	1.0 (referent)	0.0 (referent)
   Yes	Yes	6646	9,2	1.4 (1.0-2.0)	2.7 (0.1-5.2)

* RD: Rate Difference

** Adjusted for age, BMI, alcohol use, chronic renal disease, diabetes, hypertension, ischemic heart disease, use of aspirin, diuretics, and losartan, and number of GP visits.
.





